FCCC LOGO Faculty Publications
Gradishar WJ , Anderson BO , Balassanian R , Blair SL , Burstein HJ , Cyr A , Elias AD , Farrar WB , Forero A , Giordano SH , Goetz M , Goldstein LJ , Hudis CA , Isakoff SJ , Marcom PK , Mayer IA , McCormick B , Moran M , Patel SA , Pierce LJ , Reed EC , Salerno KE , Schwartzberg LS , Smith KL , Smith ML , Soliman H , Somlo G , Telli M , Ward JH , Shead DA , Kumar R
Breast Cancer, Version 1.2016
J Natl Compr Canc Netw. 2015 Dec;13(12) :1475-85
PMID: 26656517   
Back to previous list
These NCCN Guideline Insights highlight the important updates to the systemic therapy recommendations in the 2016 NCCN Guidelines for Breast Cancer. In the most recent version of these guidelines, the NCCN Breast Cancer Panel included a new section on the principles of preoperative systemic therapy. In addition, based on new evidence, the panel updated systemic therapy recommendations for women with hormone receptor-positive breast cancer in the adjuvant and metastatic disease settings and for patients with HER2-positive metastatic breast cancer. This report summarizes these recent updates and discusses the rationale behind them.
Gradishar, William J Anderson, Benjamin O Balassanian, Ron Blair, Sarah L Burstein, Harold J Cyr, Amy Elias, Anthony D Farrar, William B Forero, Andres Giordano, Sharon Hermes Goetz, Matthew Goldstein, Lori J Hudis, Clifford A Isakoff, Steven J Marcom, P Kelly Mayer, Ingrid A McCormick, Beryl Moran, Meena Patel, Sameer A Pierce, Lori J Reed, Elizabeth C Salerno, Kilian E Schwartzberg, Lee S Smith, Karen Lisa Smith, Mary Lou Soliman, Hatem Somlo, George Telli, Melinda Ward, John H Shead, Dottie A Kumar, Rashmi United States J Natl Compr Canc Netw. 2015 Dec;13(12):1475-85.